Kathryn Kennedy, MD
Psychiatry · Shreveport, LANPI 1427088020
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 34.7% of the total. Reporting peaked in 2023 at $761 and has fallen 79.9% since, to $153 in 2025.
Across 177 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$940
- Teva Pharmaceuticals USA, Inc.$436
- Alkermes, Inc.$336
- Sunovion Pharmaceuticals Inc.$189
- Lundbeck LLC$175
- Otsuka America Pharmaceutical, Inc.$162
- plus $468 from 10 others
What the payments were for
- Food & beverage$2,706100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 72 | $940 |
| Teva Pharmaceuticals USA, Inc. | 28 | $436 |
| Alkermes, Inc. | 19 | $336 |
| Sunovion Pharmaceuticals Inc. | 15 | $189 |
| Lundbeck LLC | 10 | $175 |
| Otsuka America Pharmaceutical, Inc. | 10 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $141 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $87 |
| Vanda Pharmaceuticals Inc. | 2 | $50 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Avanir Pharmaceuticals, Inc. | 2 | $40 |
| Corium, LLC | 1 | $30 |
| Indivior Inc. | 1 | $27 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $15 |
How this compares
$2,706 in reported general payments places this provider in the 80th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $10,109 |
| Divalproex Sodium | 111 | $2,537 |
| Aripiprazole | 61 | $1,577 |
| Sertraline Hcl | 168 | $1,387 |
| Fluphenazine Hcl | 12 | $1,175 |
| Trazodone Hcl | 129 | $933 |
| Doxepin Hcl | 64 | $905 |
| Gabapentin | 74 | $903 |
| Donepezil Hcl | 94 | $900 |
| Quetiapine Fumarate | 57 | $892 |
| Memantine Hcl | 43 | $840 |
| Risperidone | 65 | $620 |
| Buspirone Hcl | 33 | $578 |
| Olanzapine | 30 | $496 |
| Losartan Potassium | 39 | $437 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Shreveport
- Gregory BrownShreveport$495K
- Jasjit SinghShreveport$420K
- Suresh SabbenahalliShreveport$10K
- Guy BrannonShreveport$6K
- Christopher BernadasShreveport$6K
- Daniel FeeneyShreveport$5K
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Arwen PodestaNew Orleans$466K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.